Eighteen months after a first ticket of 19

There are several ways to get out of a tunnel. By suspending the rating of the title during the final phase of negotiations between creditors and financiers interested in the restructuring of Eurotunnel, market authorities avoid shareholders to continue to move in the dark. But, failing to commit excesses, the shareholders will always remain in an uncomfortable position. The financial equation of the group is essential. 9 Billion euros in debt, more than eleven years of sales and thirty times the gross operating surplus target expected by the Directorate, society needs significant financial sacrifices. Will any editing, bankers and investors gathered by Goldman Sachs and Macquarie accept likely to satisfy the claims of creditors on the condition to be able to enjoy the relief that they are only able to make, since, without agreement with the creditors, it is the filing of balance that clearly. However, with a market capitalization of only 1.1 billion, shareholders may find themselves strongly diluted at the end of the operation.

The cost of acceleration

Put a value on a laboratory of research in biotechnology divination is, whether is already listed in. The premium of 68 paid by AstraZeneca to acquire Cambridge Antibody Technology may seem bold. But it is consistent with other recent transactions. Eighteen months after a first ticket of 19.9 in its partner, AstraZeneca may be considered well placed to assess the quality of the teams and the prospects for further cooperation. Up to 100 upon expiry of the period which had been imposed, for recovery of CAT increased Meanwhile by almost 90, suggests that he wanted to give anyone else a chance to interfere in the place. The Group britannico-suédois is actually in a matter of urgency. Which remains sustained growth and a great mastery of its costs, its results are rather flattering and it awash with cash: the purchase of CAT will just consume 15. But its exposure to generics and doubts about the productivity of its research are investors in the reserve for the coming years. The new boss had to accelerate. And if it has sit on biotechnology one-quarter of its therapeutic developments from 2010, a set of 500 million pounds is nothing extravagant.

A silence in gold

Silver wound is not fatal. But have too much is not always a good thing for an industrial enterprise. Worn as its peers by a vigorous winter that gives a spring results especially shimmer that the escalation of the barrel is propagated to all of the energy sector, RWE stands somewhat in the European landscape. While the growth projects flourish in most of the producers and distributors of electricity and gas, the number two German seems clearly indented. To a turnover and profits that show a double-digit increase, and a debt fell by 20, to EUR 9.4 billion, RWE may prove more enterprising that the transfer of its assets in the water to the United Kingdom and the United States will continue to increase significantly its financial possibilities. However, unlike its neighbour German E.ON party to the onslaught of the Spanish Endesa, the French Suez and GDF in approximation, the Italian Enel ready to make any wood arrow or EDF to strengthen Belgium and Spain, RWE is evidence of a remarkable discretion. But maybe it is a posture purely tactical, experience showing that it is not always those that leave the first, or speak the height that the put.